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Previewssuggested by Liu et al. (2015). Potentially,
wild-type MSC-EVs could also transfer
mRNA, miRNA, cytosolic proteins, and
other membrane proteins to elicit and/or
potentiate the observed epigenetic
changes. Previous work by others
showed that MSC-EVs can upregulate
expression of a growth factor receptor in
recipient cells by transferring mRNA en-
coding the receptor (Tomasoni et al.,
2013). Whether transfer of Fas mRNA
could be an alternative mechanism to
supplement Fas function remains to be
determined.
Meanwhile, although Liu et al. (2015)
did not investigate if secretory factors
other than EVs could supplement Fas
function, it is difficult to imagine how cyto-
kines and small molecules can upregulate
Fas in cells that lack a functional Fas
gene. A complex interplay of signaling
factors is typically necessary to elicit
epigenetic changes (Mohammad and
Baylin, 2010). The ability of a secretome
to induce epigenetic changes across
Faslpr MSCs at different sites in the bone
marrow implies a more sophisticated ma-
chinery (perhaps EVs) that co-delivers
multiple signals per interaction with a
cell. Indeed, EV-mediated effects can be
so potent that in many studies, including
Liu et al. (2015), MSC-EVs alone canreproduce the therapeutic benefits of
MSCs (Rani et al., 2015). Like MSCs,
MSC-EVs have been shown to alleviate
damage in organs including the heart,
lungs, kidneys, and liver and in systemic
diseases such as graft-versus-host dis-
ease (Rani et al., 2015). Because EVs
co-deliver multiple signals, delineating
the mechanisms of action of MSC-EVs is
not straightforward. Moreover, while
MSC-EVs can directly interact with tis-
sue-specific cells as Liu et al. (2015)
demonstrate, indirect interactions should
not be overlooked. Mounting evidence in-
dicates that immune cells communicate
with each other by disseminating anti-
gen-specific information via EVs (EL An-
daloussi et al., 2013). Likewise, MSC-
EVs may interact with intermediary cells
that in turn release signals that may
include EVs to damaged tissues, launch-
ing a complex signaling network similar
to endocrine pathways. Wild-type MSC-
EVs may therefore effect epigenetic
changes in many more cell types besides
Faslpr MSCs, which could explain the
reversal of tissue damage in multiple or-
gans as observed by Liu et al. (2015).
The ability of a stem cell therapy or its
secretory products to erase pathological
‘‘memory’’ and coax diseased cells to
adopt a healthy phenotype providesCell Metabolism 2hope for regenerative medicine or even
rejuvenation. Whether such a mechanism
can be harnessed to achieve long-term
therapeutic effects, however, is worthy
of further investigation.
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Tumors are metabolically heterogeneous, and subpopulations of tumorigenic cells have been recently
described to rely more on mitochondrial respiration than glycolysis for energy production. In this issue,
Sancho et al. (2015) demonstrate that MYC is amaster switch regulatingmetabolic programs in different sub-
populations of pancreatic tumor cells.When metazoans evolved, cells lost the
ability to proliferate in response to the
availability of nutrients in the microenvi-ronment, a behavior that persists in all
single-cell beings frombacteria to eukary-
otic microorganism. The loss of nutrient-regulated proliferation is an essential
adaptation for multicellular organisms
to maintain spatial control of complex2, October 6, 2015 ª2015 Elsevier Inc. 543
Figure 1. MYC Is a Master Regulator of Cancer Metabolism
MYC is a transcriptional repressor of PGC1a and regulates the metabolic program in different sub-
populations of tumor cells. In cancer stem cells, low levels of MYC expression suppress glycolysis and
release the expression of PGC1a that, in turn, sustains mitochondrial respiration (OXPHOS). In more
differentiated cancer cells, the upregulation ofMYC is responsible for their glycolytic metabolism and the
suppression of OXPHOS. Because cancer stem cells rely on OXPHOS for their energetics, OXPHOS in-
hibitors specifically target cancer stem cells, though they can eventually develop resistance through a
partial upregulation of MYC that orchestrates an intermediate glycolytic/OXPHOS metabolism.
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Previewstissues. The uncoupling of the cell cycle
from food accessibility is achieved by
restricting cells’ access to food. Instead
of freely uptaking nutrients from interstitial
fluid, cells must first receive signals by
specific growth factors in order to pro-
liferate. Thesecoordinate ametabolic pro-
gram that induces the expression ofmem-
brane transporters and anabolic enzymes
responsible for fuel uptake and conver-
sion into biomass (Ward and Thompson,
2012). It is fascinating that in cancer, a
condition in which cells escape the tight
control of signals controlling proliferation,
cells also become independent from
exogenous signals that govern nutrient
uptake (Ward and Thompson, 2012).
Indeed, tumor cells reacquire the ability
to freely uptake food from the microenvi-
ronment, e.g., glucose, a property consid-
ered common to many tumors and widely
exploited for tumor detection using PET
imaging. In this issue, Sancho et al.
(2015) challenge this unifying view of tu-
mormetabolism isolating a subpopulation
of tumor cells characterized by decreased
dependency on glucose and increased
mitochondrial respiration (OXPHOS).544 Cell Metabolism 22, October 6, 2015 ª20The observation that tumors have
altered metabolism with respect to
normal tissues is at least a century old,
with the first formal model proposed by
Otto Warburg. Warburg’s hypothesis
that tumor cells are more glycolytic (aero-
bic glycolysis) compared to normal cells
and have defective mitochondria domi-
nated the field of cancer metabolism
for decades and was bolstered by our
progression in understanding molecular
mechanisms underlying metabolic re-
programming in cancer cells (Vander Hei-
den et al., 2009). Of course, we now have
remarkable documentation of the interre-
latedness of genetic mutations and meta-
bolic transformation, which has clarified
the role of both oncogenes and tumor
suppressor genes in driving metabolic
reprogramming in cancer cells (Kim
and Dang, 2006; Ward and Thompson,
2012). Notably, activation of KRAS and
MYC, as well as inactivation of TP53,
can extensively reprogram cell meta-
bolism, modulating several biosynthetic
pathways necessary to sustain tumor
growth. The final outcome of such meta-
bolic transformation is that cells uptake15 Elsevier Inc.more fuel independently of exogenous
signals, produce more lactate, and
consume less oxygen because carbon
skeletons in the tricarboxylic acid cycle
are diverted to fuel anabolic reactions
for biomass synthesis instead of being
completely oxidized to produce ATP
through respiration. Indeed, aerobic
glycolysis is an essential tumor adapta-
tion mechanism; however, a growing
body of evidence supports the idea
that tumors are much more heteroge-
neous than previously thought, and that
aerobic glycolysis represents just one
aspect of a complex metabolic landscape
among tumor cells (Viale et al., 2015).
A small population of slow-growing cells
endowed with tumorigenic potential,
self-renewal capabilities, and intrinsic
resistance to conventional and targeted
therapies has been isolated and char-
acterized in different tumors. These cells
seem to rely on more active mitochon-
dria than other tumor cells and show an
increased consumption of oxygen (Laga-
dinou et al., 2013; Roesch et al., 2013; Vi-
ale et al., 2014). Interestingly, a common
trait among this subpopulation of cells
is their decreased glycolytic capacity
and the inability to upregulate glycolysis
in response to the inhibition of mitochon-
drial respiration. This is a critical feature
of the metabolism of tumorigenic cells,
revealing a lack of energetic compensa-
tory mechanisms (Viale et al., 2014). The
strict dependency on OXPHOS for main-
taining energy requirements has lead
several authors to propose the use of in-
hibitors of OXPHOS to selectively eradi-
cate cancer stem cells preventing tumor
relapse after treatment (Roesch et al.,
2013; Skrtic et al., 2011; Viale et al.,
2014, 2015; Wolf, 2014). With this ambi-
tious goal, some promising candidates,
such as tigecycline, are already under
clinical investigation.
In this issue ofCell Metabolism, Sancho
et al. (2015), using cells isolated from hu-
man primary tumors, demonstrated that
pancreatic cancers are metabolically
heterogeneous, with metabolic programs
activated in different subpopulations of
cells: cancer stem cells rely on OXPHOS
and have decreased glycolytic activity
with respect to their more differentiated
progeny. Because cancer stem cells
do not compensate inhibition of mito-
chondrial respiration with an increase in
glycolysis, the authors demonstrated
Cell Metabolism
Previewsthat targeting OXPHOS is a useful
approach to eliminate tumorigenic cells
in xenograft models of patient-derived
tumor. Indeed, treatment with Metformin,
a complex I inhibitor widely used as
hypoglycemic drug in type 2 diabetes,
induces specifically metabolic stress
and apoptosis in cancer stem cells and,
consequently, a reduction of CD133+
tumorigenic cells in tumors in vivo. How-
ever, eventually metformin resistance
emerges and tumors regrow. Interest-
ingly, the authors found that cancer stem
cells resistant to OXPHOS inhibition
activated a glycolytic program, acquiring
an ‘‘intermediate glycolytic/respiratory’’
metabolism. Transcriptional analysis
comparing cancer stem cells with their
differentiated progeny and resistant can-
cer stem cells revealed that expression
of MYC was increased in OXPHOS inhib-
itor-resistant cancer stem cells at levels
comparable to those found in more differ-
entiated tumor cells. Importantly, the au-
thors demonstrated that MYC acted as
the ‘‘main switch’’ between glycolytic
and oxidative metabolism in cancer cells;
indeed, they demonstrated that MYC is a
direct transcriptional inhibitor of the mito-
chondrial master regulator Peroxisome
proliferator-activated receptor gamma
coactivator 1-alpha (PGC1a). As a conse-
quence, expression of MYC activates
glycolytic programs on one hand and sup-
presses mitochondrial respiration on theother, thus regulating the transition be-
tween cancer stem cells and their more
differentiated progeny and explaining the
‘‘intermediate metabolism’’ of OXPHOS
inhibitor-resistant cancer stem cells as
well (Figure 1).
These findings uncover new molecular
mechanisms responsible for metabolic
heterogeneity in pancreatic tumors and
identify an unexpected function of MYC.
This work raises important questions
as well. For example, if activated onco-
genes have the ability to reprogram the
metabolism of transformed cells, why is
their outcome different in distinct sub-
populations of cells? In other words, if
KRAS is expressed in all the tumor sub-
populations, why does it exert different
metabolic effects in cancer stem cells,
their differentiated progeny, and eventu-
ally in OXPHOS inhibitor-resistant can-
cer stem cells? Why is MYC activated in
only some subpopulations and not in
others?
These data portend a model in which
the effects of activated oncogenes on
metabolic reprogramming are not univer-
sal but context-specific such that the
extent of the effect of KRAS activation
on tumor metabolism is strongly depen-
dent on the differentiation state of the tu-
mor cells. Uncovering the molecular basis
for this specificity with regard to differen-
tial oncogenic reprogramming of cellular
metabolism will be a critical next step inCell Metabolism 2understanding tumor heterogeneity and
complexity.REFERENCES
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